Inhaled human insulin (Exubera®): clinical profile and patient considerations

Keyphrases

• Clinical Profile 100%
• Clinical Patients 100%
• Exubera 100%
• Human Insulin 100%
• Oral Agents 37%
• Subcutaneous Insulin 25%
• Glycemic Control 12%
• Insulin 12%
• Hyperglycemia 12%
• Adverse Effects 12%
• Type 2 Diabetes Mellitus (T2DM) 12%
• Monotherapy 12%
• Hemoglobin A1c (HbA1c) 12%
• Hypoglycemia 12%
• Insulin Therapy 12%
• Safety Profile 12%
• Rapid-acting 12%
• Adult Patients 12%
• Subcutaneous Administration 12%
• Treatment Options 12%
• Long-term Safety 12%
• Moderate to Severe 12%
• Subcutaneous Injection 12%
• Cough 12%
• Patient Satisfaction 12%
• Increased Incidence 12%
• Regular Human Insulin 12%
• Safety Data 12%
• Rapid-acting Insulin 12%
• Pulmonary Function 12%
• Treatment Discontinuation 12%
• Oral Inhalation 12%
• HbA1c Control 12%
• Insulin Antibodies 12%

Medicine and Dentistry

• Human Insulin 100%
• Recombinant Human Insulin 100%
• Hemoglobin A1c 18%
• Subcutaneous Injection 18%
• Monotherapy 9%
• Exhalation 9%
• Maturity Onset Diabetes of the Young 9%
• Adverse Event 9%
• Hypoglycemia 9%
• Hyperglycemia 9%
• Insulin Treatment 9%
• Glycemic Control 9%
• Coughing 9%
• Patient Satisfaction 9%
• Insulin Derivative 9%
• Lung Function 9%
• Insulin Antibody 9%
• Short Acting Insulin 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Recombinant Human Insulin 100%
• Human Insulin 100%
• Hemoglobin A1c 18%
• Subcutaneous Injection 18%
• Hyperglycemia 9%
• Adverse Event 9%
• Non Insulin Dependent Diabetes Mellitus 9%
• Monotherapy 9%
• Hypoglycemia 9%
• Coughing 9%
• Insulin Antibody 9%
• Insulin Analog 9%
• Short Acting Insulin 9%